Latest From 23andMe Inc.
Deal news from GeoVax/BravoVax, Onconova/HanX, Zydus Cadila/China Medical System Holdings, EyePoint/Ocumension, Ningbo NewBay Medical/Genentech, Otsuka/PhoreMost, Almirall/WuXi Biologics
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.
- Drug Discovery Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Saliva-based Testing
- Laboratory Testing Services
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- 23andMe Inc.
- Senior Management
Anne Wojcicki, CEO
Dean Schorno, CFO & Head, Operations
Richard Scheller, PhD, CSO & Head, Therapeutics
Joyce Tung, PhD, VP, Research
Steve Lemon, VP, Product & Engineering
Kathy Hibbs, JD, Chief Legal & Regulatory Officer
Emily Drabant Conley, PhD, VP, BD
Robert Gentleman, PhD, VP, Computational Biology
Jonathan Ward, VP, Consumer Marketing & Acquisition
Tracy Keim, MS, VP, Consumer Marketing & Brand
- Contact Info
Phone: (650) 938-6300
899 West Evelyn Ave.
Mountain View, CA 94041
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.